Navigation Links
Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
Date:5/15/2008

WAYNE, N.J. and EMERYVILLE, Calif., May 16 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced more than 40 data presentations at the 2008 American Society of Clinical Oncology (ASCO) annual meeting demonstrating the potential for Nexavar(R) (sorafenib) tablets in multiple tumor types as a single agent or in combination with other agents.

"Data at ASCO will expand upon and support the proven efficacy and tolerability of Nexavar in liver cancer and advanced kidney cancer and provide new insight into the potential of Nexavar in additional types of cancer," said Henry Fuchs, MD, executive vice president and chief medical officer of Onyx Pharmaceuticals. "Highlights include studies demonstrating that Nexavar extends life for Asian patients with liver cancer; provides an effective, well-tolerated option for elderly patients with advanced kidney cancer and may provide benefit and warrants further study in heavily pretreated patients with non-small cell lung cancer."

Nexavar data highlights include:

Hepatocellular Carcinoma

-- Randomized Phase III trial of sorafenib versus placebo in Asian

patients with advanced hepatocellular carcinoma

-- Ann Lii-Cheng, MD, PhD, department of internal medicine, National

Taiwan University Hospital, Taipei, Taiwan

-- Abstract #4509, oral presentation, Monday, June 02, 2008,

4:30 - 4:45 p.m., E-Hall D2

-- Efficacy and safety of sorafenib in patients with advanced

hepatocellular carcinoma and vascular invasion or extrahepatic spread:

a subanalysis from the SHARP trial

-- Morris Sherman, MD, PhD, associate professor of medic
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; OnyxPharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bayer CropSciences Vegetable Seed Business Nunhems Acquires US Lettuce Seed Company Paragon Seed
2. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
3. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
4. Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement
5. Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx
6. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
7. Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)CALGARY, Dec. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ: ONCY ) announced today that in connection with its previously announced unit offering
(Date:12/2/2009)JERUSALEM, Israel, December 2 Gamida Cell announced today,a feasibility study evaluating the preclinical (animal study) safety and,efficacy of a gene therapy product which combines technology from We
(Date:12/2/2009)QUEBEC CITY, Dec. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today annou
(Date:12/1/2009)Dr. Kerry Solomon announced that he has joined Carolina Eyecare Physicians and has launched his redesigned website at www.DrKerrySolomon.com , which was developed by Medical Consulting Group. Dr. So
Breaking Biology Technology:Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 2Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 4Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 5Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 6
...I and Endovascular Forum Launch Interactive, Case-...ide Learning and Collaboration , , LAS VEGAS, May...e complication, another physician has likely seen ...iovascular Angiography and Interventions (SCAI) an...es Company, today unveiled a new educational Websi...
...TTLE, May 6 Dendreon Corporation (Nasdaq: DNDN ...ed March 31, 2009. Revenue for the first quarter ...arter ended March 31, 2008. , , Dendreon,s tota...rch 31, 2009 were $17.0 million compared to $19.2 ... for the quarter ended March 31, 2009 was $15.4 mi...
...MBRIDGE, Mass. May 5, 2009 Researchers at the Ha...SEAS), in collaboration with researchers from Worc...ed, for the first time, that the activation energy...ted by the surrounding dielectric and can be modif.... , The finding, published in the April 6 issue o...
Other Biology Technology:New Website Connects Physicians to Solve Challenging Cases and Share Experiences 2New Website Connects Physicians to Solve Challenging Cases and Share Experiences 3New Website Connects Physicians to Solve Challenging Cases and Share Experiences 4Dendreon Reports First Quarter 2009 Financial Results 2Dendreon Reports First Quarter 2009 Financial Results 3Dendreon Reports First Quarter 2009 Financial Results 4Dendreon Reports First Quarter 2009 Financial Results 5Scientists demonstrate effect of confining dielectrics on semiconductor nanowire conductivity 2
(Date:12/3/2009)Have you ever felt overly upset by a social snubbing? Your genetics, not your friends, may be at fault. , Scientists have long known that opium-like painkillers, called opioids, relieve not only phys
(Date:12/3/2009)The 30-year record low in Antarctic snowmelt that occurred during the 2008-09 austral summer was likely due to concurrent strong positive phases for two main climate drivers, ENSO (El Nio - Southern O
(Date:12/2/2009)PHILADELPHIA People who smoke their first cigarette within minutes after waking up have much higher levels of cotinine, a by-product of nicotine when processed by the body, than those who wait to smo
Breaking Biology News(10 mins):CCNY professor foresees rising Antarctic snowmelt 2Increased nicotine levels detected in those who light-up earlier 2Data from Jazz Pharmaceuticals First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia to be Presented at Upcoming Conferences 5493 1Data from Jazz Pharmaceuticals First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia to be Presented at Upcoming Conferences 5493 2Data from Jazz Pharmaceuticals First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia to be Presented at Upcoming Conferences 5493 3New 2009 Cumulative Supplement to Pharmaceutical Patent Law Examines Critical Intersection Of Patent Law and Food And Drug Law 59490 1New 2009 Cumulative Supplement to Pharmaceutical Patent Law Examines Critical Intersection Of Patent Law and Food And Drug Law 59490 2New 2009 Cumulative Supplement to Pharmaceutical Patent Law Examines Critical Intersection Of Patent Law and Food And Drug Law 59490 3American Academy of Physician Assistants Applauds Senate Finance Committee for Advancing Health Reform Legislation 59488 1American Academy of Physician Assistants Applauds Senate Finance Committee for Advancing Health Reform Legislation 59488 2
...dence suggesting an alternative form of natural vi...lood in humans at levels determined to protect aga...rs naturally in eight different forms. The primary...ol, or TCP. But another natural form of vitamin E ...eated Ohio State University Medical Center studies...
...g smoking can improve lung function test scores by... The findings appear in the second issue for July ...itical Care Medicine, published by the American Th...Departments of Respiratory Medicine and Immunology...s studied 11 asthmatics who continued to smoke and...
...hildren under age 6 in Massachusetts over 22 years...n--especially infants--are now more likely to be o...of Ambulatory Care and Prevention of Harvard Medic...ars in the July issue of Obesity. , "The obesity e... children," says Matthew Gillman, MD, senior autho...
Other Biology News:Natural vitamin E tocotrienol reaches blood at protective levels 2Natural vitamin E tocotrienol reaches blood at protective levels 3Quitting smoking improves lung function considerably 2Today's babies are fatter babies 2
pYES2 from Invitrogen
Nunc MicroWell Mini Trays from Invitrogen
Rabbit Anti-Human MTHFD1 Polyclonal Antibody, Unconjugated from Atlas Antibodies
GIBCO Improved MEM Zn++ Option (Richter's Modification) liquid from Invitrogen
Biology Products: